Bukwang Pharmaceutical Co., Ltd. announced on March 3rd that they signed an export agreement for Dexid Tab., an incrementally modified product for diabetic neuropathy developed by Bukwang. The agreement was made with Kalbe International Pte. Ltd. to export Dexid Tab. to 6 countries including the Philippines and Vietnam. ![]()
Dexid Tab. was developed in-house at Bukwang and launched in Korea early 2014. Dexid Tab. only includes the R-form of the thioctic acid, which is the main ingredient of Thioctacid, a product for diabetic neuropathy. Thioctic acid exists as a racemate but the R-form is the major active form. Therefore, Dexid Tab. retains the efficacy of Thioctacid while having reduced dose of 480 as opposed to 600mg of Thioctacid. This change has the benefit of improving patients’ compliance.
Bukwang is exploring the overseas market for toothpastes and nutritional supplements as well as therapeutics. In this way, Bukwang aims to further activate their overseas business. |